FDNA Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 23

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $27.5M

  • Investors
  • 3

FDNA General Information

Description

Developer of an AI-based phenotyping technology designed to analyze relevant genomic and phenotypic information. The company's technology detects physiological patterns that reveal disease-causing genetic variations, which are analyzed and included in their comprehensive database of clinically relevant genomic and phenotypic information, enabling clinicians, labs, and researchers to address genetic disease problems in healthcare.

Contact Information

Website
www.fdna.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Primary Office
  • 490 Sawgrass Corporate Parkway
  • Suite 200
  • Sunrise, FL 33325
  • United States
+1 (954) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

FDNA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series B) $27.5M 000.00 00000 Completed Generating Revenue
To view FDNA’s complete valuation and funding history, request access »

FDNA Patents

FDNA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10667689-B2 Systems, methods, and computer-readable media for patient image analysis to identify new diseases Active 08-Jun-2017 0000000000
US-20190261854-A1 Systems, methods, and computer-readable media for patient image analysis to identify new diseases Active 08-Jun-2017 000000000
US-20180353072-A1 Systems, methods, and computer-readable media for gene and genetic variant prioritization Active 08-Jun-2017 000000000
US-10327637-B2 Systems, methods, and computer-readable media for patient image analysis to identify new diseases Active 08-Jun-2017 000000000
US-10470659-B2 Systems, methods, and computer-readable media for gene and genetic variant prioritization Active 08-Jun-2017 G06V10/82
To view FDNA’s complete patent history, request access »

FDNA Executive Team (12)

Name Title Board Seat Contact Info
Andy Saffarian Chief Executive Officer
Christen Baglaneas Director, Corporate Communications
Peter Krawitz MD Chief Data Science Officer
Lior Wolf Ph.D Co-Founder
Karen Gripp MD Chief Medical Officer
You’re viewing 5 of 12 executive team members. Get the full list »

FDNA Board Members (6)

Name Representing Role Since
Assaf Segal Self Board Member 000 0000
Karen Madden Self Board Observer 000 0000
Moti Shniberg Self Co-Founder & Chairman 000 0000
Robin Woodhead FDNA Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

FDNA Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FDNA Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Clal Biotechnology Industries Venture Capital Minority 000 0000 000000 0
HCS Capital (Israel) Venture Capital Minority 000 0000 000000 0
Nacre Capital Accelerator/Incubator Minority 000 0000 000000 0
To view FDNA’s complete investors history, request access »